305 related articles for article (PubMed ID: 33870733)
1. Sacubitril/valsartan treatment has differential effects in modulating diabetic kidney disease in
Myakala K; Jones BA; Wang XX; Levi M
Am J Physiol Renal Physiol; 2021 Jun; 320(6):F1133-F1151. PubMed ID: 33870733
[TBL] [Abstract][Full Text] [Related]
2. Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness.
Aroor AR; Mummidi S; Lopez-Alvarenga JC; Das N; Habibi J; Jia G; Lastra G; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2021 Apr; 20(1):80. PubMed ID: 33882908
[TBL] [Abstract][Full Text] [Related]
3. The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat.
Habibi J; Aroor AR; Das NA; Manrique-Acevedo CM; Johnson MS; Hayden MR; Nistala R; Wiedmeyer C; Chandrasekar B; DeMarco VG
Cardiovasc Diabetol; 2019 Mar; 18(1):40. PubMed ID: 30909895
[TBL] [Abstract][Full Text] [Related]
4. Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice.
Esser N; Schmidt C; Barrow BM; Cronic L; Hackney DJ; Mongovin SM; Hogan MF; Templin AT; Castillo JJ; Hull RL; Zraika S
Front Endocrinol (Lausanne); 2022; 13():888867. PubMed ID: 35733766
[TBL] [Abstract][Full Text] [Related]
5. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
6. Sacubitril/valsartan ameliorates renal tubulointerstitial injury through increasing renal plasma flow in a mouse model of type 2 diabetes with aldosterone excess.
Nishio H; Ishii A; Yamada H; Mori KP; Kato Y; Ohno S; Handa T; Sugioka S; Ishimura T; Ikushima A; Inoue Y; Minamino N; Mukoyama M; Yanagita M; Yokoi H
Nephrol Dial Transplant; 2023 Oct; 38(11):2517-2527. PubMed ID: 37202215
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury.
Uijl E; 't Hart DC; Roksnoer LCW; Groningen MCC; van Veghel R; Garrelds IM; de Vries R; van der Vlag J; Zietse R; Nijenhuis T; Joles JA; Hoorn EJ; Danser AHJ
J Hypertens; 2020 Apr; 38(4):755-764. PubMed ID: 31790054
[TBL] [Abstract][Full Text] [Related]
8. Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF.
Schauer A; Adams V; Augstein A; Jannasch A; Draskowski R; Kirchhoff V; Goto K; Mittag J; Galli R; Männel A; Barthel P; Linke A; Winzer EB
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33808232
[TBL] [Abstract][Full Text] [Related]
9. Sacubitril/valsartan reduces susceptibility to atrial fibrillation by improving atrial remodeling in spontaneously hypertensive rats.
Li Q; Fang Y; Peng DW; Li LA; Deng CY; Yang H; Kuang SJ; Li QQ; Zhang MZ; Zeng P; Zhang QH; Liu Y; Deng H; Wei W; Xue YM; Wu SL; Rao F
Eur J Pharmacol; 2023 Aug; 952():175754. PubMed ID: 37182595
[TBL] [Abstract][Full Text] [Related]
10. Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation.
Mochel JP; Teng CH; Peyrou M; Giraudel J; Danhof M; Rigel DF
Eur J Pharm Sci; 2019 Feb; 128():103-111. PubMed ID: 30508581
[TBL] [Abstract][Full Text] [Related]
11. Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice.
Li X; Zhu Q; Wang Q; Zhang Q; Zheng Y; Wang L; Jin Q
Cardiovasc Drugs Ther; 2020 Oct; 34(5):629-640. PubMed ID: 32444995
[TBL] [Abstract][Full Text] [Related]
12. Sacubitril/valsartan mitigates cardiac remodeling, systolic dysfunction, and preserves mitochondrial quality in a rat model of mitral regurgitation.
Tantisuwat L; Saengklub N; Boonpala P; Kumphune S; Panyasing Y; Kalandakanond-Thongsong S; Kijtawornrat A
Sci Rep; 2023 Jul; 13(1):11472. PubMed ID: 37455281
[TBL] [Abstract][Full Text] [Related]
13. Combined levosimendan and Sacubitril/Valsartan markedly protected the heart and kidney against cardiorenal syndrome in rat.
Sung PH; Chai HT; Yang CC; Chiang JY; Chen CH; Chen YL; Yip HK
Biomed Pharmacother; 2022 Apr; 148():112745. PubMed ID: 35202913
[TBL] [Abstract][Full Text] [Related]
14. The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review.
Zhang R; Sun X; Li Y; He W; Zhu H; Liu B; Zhang A
J Cardiovasc Pharmacol Ther; 2022; 27():10742484211058681. PubMed ID: 34994233
[TBL] [Abstract][Full Text] [Related]
15. Sacubitril/Valsartan Decreases Cardiac Fibrosis in Left Ventricle Pressure Overload by Restoring PKG Signaling in Cardiac Fibroblasts.
Burke RM; Lighthouse JK; Mickelsen DM; Small EM
Circ Heart Fail; 2019 Apr; 12(4):e005565. PubMed ID: 30998392
[TBL] [Abstract][Full Text] [Related]
16. Beneficial and harmful effects of sacubitril/valsartan in patients with heart failure: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis.
Nielsen EE; Feinberg JB; Bu FL; Hecht Olsen M; Raymond I; Steensgaard-Hansen F; Jakobsen JC
Open Heart; 2020 Nov; 7(2):. PubMed ID: 33257469
[TBL] [Abstract][Full Text] [Related]
17. Strain-selective efficacy of sacubitril/valsartan on carotid fibrosis in response to injury in two inbred mouse strains.
Korshunov VA; Quinn B; Faiyaz A; Ahmed R; Sowden MP; Doyley MM; Berk BC
Br J Pharmacol; 2019 Aug; 176(15):2795-2807. PubMed ID: 31077344
[TBL] [Abstract][Full Text] [Related]
18. Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date.
Vilela-Martin JF
Drug Des Devel Ther; 2016; 10():1627-39. PubMed ID: 27274196
[TBL] [Abstract][Full Text] [Related]
19. Sacubitril/Valsartan inhibits M1 type macrophages polarization in acute myocarditis by targeting C-type natriuretic peptide.
Liu C; Long Q; Yang H; Yang H; Tang Y; Liu B; Zhou Z; Yuan J
Biomed Pharmacother; 2024 May; 174():116535. PubMed ID: 38581923
[TBL] [Abstract][Full Text] [Related]
20. Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure.
Marques da Silva P; Aguiar C
Rev Port Cardiol; 2017 Sep; 36(9):655-668. PubMed ID: 28844335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
